G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was refreshing and relaxing because that relentless routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? As always, we are coping by quaffing multiple cups of stimulation — alternating between Cinnamon Dolce and Southern Pecan, if you care — and invite you to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Hope you have a terrifically productive day and do keep in touch …

GlaxoSmithKline may pay $10 billion to expand its consumer health care business by purchasing the 36.5 percent stake that Novartis holds in its Consumer Healthcare unit, The Sunday Times tells us. The joint venture was set up in April 2014 as part of a larger asset swap between the two companies. Novartis has an option to sell the stake back to Glaxo, which comes into force next March. And Novartis could use the proceeds to finance a large takeover.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.